PMID- 34766699
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220719
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 21
IP  - 7
DP  - 2022 Jul
TI  - Real-life experience of a lidocaine/tetracaine self-occluding topical anesthetic 
      for dermatological procedures.
PG  - 2939-2944
LID - 10.1111/jocd.14583 [doi]
AB  - BACKGROUND: Pliaglis((R)) is a self-occluding topical anesthetic containing a 
      eutectic mixture of 7% lidocaine and 7% tetracaine, with proven efficacy and 
      safety in several trials. AIMS: To evaluate the effectiveness and safety of 
      Pliaglis((R)) for different dermatological procedures in real-life clinical 
      practice. METHODS: This retrospective, multicenter study included 35 patients 
      treated with Pliaglis((R)) prior to five dermatological procedures (pulsed dyed 
      laser, picosecond laser, non-ablative fractional laser, radiofrequency 
      microneedling, and photodynamic therapy). The primary endpoint was to assess the 
      pain during the procedure with a visual analogue score (VAS) from 0 (no pain) to 
      10 (most severe pain). Secondary endpoints were the global effectiveness and 
      tolerability (from 0 = very low to 10 = excellent), and the adverse events (AEs) 
      after Pliaglis((R)) removal, classified according to intensity (1-3). RESULTS: The 
      median and mean pain VAS reported by patients was 2 (range 0-9) and 2.9 (+/-2.3), 
      respectively. More than 65% of the patients had a VAS score </=3. The effectiveness 
      reported by investigators was "very good" (median 8 [range 2-10], mean 7.5 
      [+/-1.9]), which was strongly correlated with the pain VAS reported by patients 
      (Spearman coefficient = - 0.9; p < 0.001). Forty-five percent of patients 
      reported AEs and they were transient and mostly mild, with a mean intensity score 
      of 1.5 (range 1-3). Tolerability of Pliaglis((R)) was reported by investigators as 
      "excellent" (median 10 [range 1-10], mean 9 [+/-1.8]). CONCLUSIONS: Pliaglis((R)) is 
      an effective topical anesthetic for several dermatological procedures, with an 
      excellent safety and tolerability profile.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Jimenez-Cauhe, Juan
AU  - Jimenez-Cauhe J
AUID- ORCID: 0000-0002-6190-0147
AD  - Servicio de Dermatologia, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Boixeda, Pablo
AU  - Boixeda P
AD  - Servicio de Dermatologia, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Cornejo, Paloma
AU  - Cornejo P
AD  - Clinica Dra Paloma Cornejo, Madrid, Spain.
FAU - Fernandez, Sergio
AU  - Fernandez S
AD  - Clinica Le Med, Madrid, Spain.
FAU - Vitale, Maria
AU  - Vitale M
AD  - Departamento Medico. Cantabria Labs, Madrid, Spain.
FAU - Serra, Carlos
AU  - Serra C
AD  - Servicio de Dermatologia, Instituto Valenciano de Oncologia (IVO), Valencia, 
      Spain.
LA  - eng
GR  - Cantabria Labs/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211112
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
RN  - 0 (Anesthetics, Local)
RN  - 0619F35CGV (Tetracaine)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Administration, Topical
MH  - *Anesthetics, Local/adverse effects
MH  - Double-Blind Method
MH  - Humans
MH  - Lidocaine/adverse effects
MH  - Pain/chemically induced
MH  - Pain Measurement
MH  - Retrospective Studies
MH  - *Tetracaine/adverse effects
OTO - NOTNLM
OT  - Pliaglis
OT  - dermatological procedures
OT  - lidocaine
OT  - self-occluding
OT  - tetracaine
OT  - topical anesthetic
EDAT- 2021/11/13 06:00
MHDA- 2022/07/20 06:00
CRDT- 2021/11/12 08:49
PHST- 2021/05/15 00:00 [received]
PHST- 2021/10/18 00:00 [accepted]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2021/11/12 08:49 [entrez]
AID - 10.1111/jocd.14583 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2022 Jul;21(7):2939-2944. doi: 10.1111/jocd.14583. Epub 2021 
      Nov 12.